p53 Is a transcriptional activator of the muscle-specific phosphoglycerate mutase gene and contributes in vivo to the control of its cardiac expression

Cell Growth and Differentiation

Volumn 10, Issue 5, 1999, Pages 295-306

  Ruiz Lozano, Pilar ^a,b   Hixon, Mary L ^a   Wagner, Mark W ^a   Flores, Ana I ^a   Ikawa, Shuntaro ^c   Baldwin Jr , Albert S ^d   Chien, Kenneth R ^b   Gualberto, Antonio ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c TOHOKU UNIVERSITY   (Japan)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PHOSPHOGLYCERATE MUTASE; PROTEIN P53;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; EMBRYO; GENETIC TRANSFECTION; HEART CELL CULTURE; IN SITU HYBRIDIZATION; IN VIVO STUDY; MOUSE; MYOBLAST; MYOTUBE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; SITE DIRECTED MUTAGENESIS; TRANSACTIVATION;

ANIMALS; CELL LINE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MICE; MUSCLE, SKELETAL; MYOCARDIUM; PHOSPHOGLYCERATE MUTASE; PROMOTER REGIONS (GENETICS); RATS; RESPONSE ELEMENTS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032975551     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Schultheiss, T. M., Xydas, S., and Lassar, A. B. Induction of avian cardiac myogenesis by anterior endoderm. Development (Camb.), 121: 4203-4214, 1995.
2. Sugi, Y., and Lough, J. Anterior endoderm is a specific effector of terminal cardiac myocyte differentiation of cells from the embryonic heart forming region. Dev. Dyn., 200: 155-162, 1994.
3. Olson, E. N., and Srivastava, D. Molecular pathways controlling heart development. Science (Washington DC), 272: 671-676, 1996.
4. Nakatsuji, Y., Hidaka, K., Tsujino, S., Yamamoto, Y., Mukai, T., Yanagihara, T., Kishimoto, T., and Sakoda, S. A single MEF-2 site is a major positive regulatory element required for transcription of the muscle-specific subunit of the human phosphoglycerate mutase gene in skeletal and cardiac muscle cells. Mol. Cell. Biol., 12: 4384-4390, 1992.
5. Ruiz-Lozano, P., de Lecea, L., Buesa, C., Perez de la Osa, P., LePage, D., Gualberto, A., Walsh, K., and Pons, G. The gene encoding rat phosphoglycerate mutase subunit M: cloning and promoter analysis in skeletal muscle cells. Gene, 147: 243-248, 1994.
6. Adamson, E. D. Isoenzyme transitions of creatine phosphokinase, aldolase and phosphoglycerate mutase in differentiating mouse cells. J. Embryol. Exp. Morphol., 35: 355-367, 1976.
7. Weintraub, H., Hauschka, S., and Tapscott, S. J. The MCK enhancer contains a p53 responsive element. Proc. Natl. Acad. Sci. USA, 88: 4570-4571, 1991.
8. Zambetti, G. P., Bargonetti, J., Walker, K., Prives, C., and Levine, A. J. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev., 6: 1143-1152, 1992.
9. Tamir, Y., and Bengal, E. p53 protein is activated during muscle differentiation and participates with MyoD in the transcription of muscle creatine kinase gene. Oncogene, 17: 347-356, 1998.
10. Zhao, J., Schmieg, F. I., Logsdon, N., Freedman, D., Simmons, D. T., and Molloy, G. R. p53 binds to a novel recognition sequence in the proximal promoter of the rat muscle creatine kinase gene and activates its transcription. Oncogene, 13: 293-302, 1996.
11. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
12. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (Lond.), 358: 80-83, 1992.
13. Soddu, S., Blandino, G., Scardigli, R., Coen, S., Marchetti, A., Rizzo, M. G., Bossi, G., Cimino, L., Crescenzi, M., and Sacchi, A. Interference with p53 protein inhibits hematopoietic and muscle differentiation. J. Cell Biol., 134: 193-204, 1996.
14. Chen, P. L., Chen, Y. M., Bookstein, R., and Lee, W. H. Genetic mechanisms of tumor suppression by the human p53 gene. Science (Washington DC), 250: 1576-1580, 1990.
15. Kern, S. E., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W., and Vogelstein, B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (Washington DC), 256: 827-830, 1992.
16. Harvey, M., Vogel, H., Morris, D., Bradley, A., Bernstein, A., and Donehower, L. A. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet., 9: 305-311, 1995.
17. Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., and Prives, C. Wild-type p53 activates transcription in vitro. Nature (Lond.), 353: 83-86, 1992.
18. Schmale, H., and Bamberger, C. A novel protein with strong homology to the tumor suppressor p53. Oncogene, 15: 1363-1367, 1997.
19. Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M., and Ikawa, S. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med., 4: 839-843, 1998.
20. Trink, B., Okami, K., Wu, L., Sriuranpong, V., Jen, J., and Sidransky, D. A new human p53 homologue. Nat. Med., 4: 747-748, 1998.
21. Bian, J., and Sun, Y. p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: a third member of the p53 family? Proc. Natl. Acad. Sci. USA, 94: 14753-14758, 1997.
22. Jost, C. A., Marin, M. C., and Kaelin, W. G., Jr. p73 is a human p53-related protein that can induce apoptosis. Nature (Lond.), 389: 191-194, 1997.
23. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J. C., Valent, A., Minty, A., Chalon, P., Lelias, J. M., Dumont, X., Ferrara, P., McKeon, F., and Caput, D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 90: 809-819, 1997.
24. Di Como, C. J., Gaiddon, C., and Prives, C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol., 19: 1438-1449, 1999.
25. Senoo, M., Seki, N., Ohira, M., Sugano, S., Watanabe, M., Inuzuka, S., Okamoto, T., Tachibana, M., Tanaka, T., Shinkai, Y., and Kato, H. A second p53-related protein, p73L, with high homology to p73. Biochem. Biophys. Res. Commun., 248: 603-607, 1998.
26. Harris, A. N., Ruiz-Lozano, P., Chen, Y. F., Sionit, P., Yu, Y. T., Lilly, B., Olson, E. N., and Chien, K. R. A novel A/T-rich element mediates ANF gene expression during cardiac myocyte hypertrophy. J. Mol. Cell. Cardiol., 29: 515-525, 1997.
27. Zhu, H., Garcia, A. V., Ross, R. S., Evans, S. M., and Chien, K. R. A conserved 28-base-pair element (HF-1) in the rat cardiac myosin light-chain-2 gene confers cardiac-specific and α-adrenergic-inducible expression in cultured neonatal rat myocardial cells. Mol. Cell. Biol., 11: 2273-2281, 1991.
28. Wang, Y., Reed, M., Wang, P., Stenger, J. E., Mayr, G., Anderson, M. E., Schwedes, J. F., and Tegtmeyer, P. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev., 7: 2575-2586, 1993.
29. Pavletich, N. P., Chambers, K. A., and Pabo, C. O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev., 7: 2556-2564, 1993.
30. Bargonetti, J., Manfredi, J. J., Chen, X., Marshak, D. R., and Prives, C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev., 7: 2565-2574, 1993.
31. Banks, L., Matlashewski, G., and Crawford, L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem., 159: 529-534, 1986.
32. Vojtesek, B., Bartek, J., Midgley, C. A., and Lane, D. P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods, 151: 237-244, 1992.
33. Hupp, T. R., Meek, D. W., Midgley, C. A., and Lane, D. P. Regulation of the specific DNA binding function of p53. Cell, 71: 875-886, 1992.
34. Gannon, J. V., Greaves, R., Iggo, R., and Lane, D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J., 9: 1595-1602, 1990.
35. Andres, V., Cusso, R., and Carreras, J. Distribution and developmental transition of phosphoglycerate mutase and creatine phosphokinase isozymes in rat muscles of different fiber-type composition. Differentiation, 41: 72-77, 1989.
36. Kim, K. K., Soonpaa, M. H., Daud, A. I., Koh, G. Y., Kim, J. S., and Field, L. J. Tumor suppressor gene expression during normal and pathologic myocardial growth. J. Biol. Chem., 269: 22607-22613, 1994.
37. Sah, V. P., Attardi, L. D., Mulligan, G. J., Williams, B. O., Bronson, R. T., and Jacks, T. A subset of p53-deficient embryos exhibit exencephaly. Nat. Genet., 10: 175-180, 1995.
38. Schmid, P., Lorenz, A., Hameister, H., and Montenarh, M. Expression of p53 during mouse embryogenesis. Development (Camb.), 113: 857-865, 1991.
39. Armstrong, J. F., Kaufman, M. H., Harrison, D. J., and Clarke, A. R. High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol., 5: 931-936, 1995.
40. Unger, T., Mietz, J. A., Scheffner, M., Yee, C. L., and Howley, P. M. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol. Cell. Biol., 13: 5186-5194, 1993.
41. Hachiya, M., Chumakov, A., Miller, C. W., Akashi, M., Said, J., and Koeffler, H. P. Mutant p53 proteins behave in a dominant, negative fashion in vivo. Anticancer Res., 14: 1853-1859, 1994.
42. Chen, J. Y., Funk, W. D., Wright, W. E., Shay, J. W., and Minna, J. D. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene, 8: 2159-2166, 1993.
43. Louis, J. M., McFarland, V. W., May, P., and Mora, P. T. The phosphoprotein p53 is down-regulated post-transcriptionally during embryogenesis in vertebrates. Biochim. Biophys. Acta, 950: 395-402, 1988.
44. Feinstein, E., Gale, R. P., Reed, J., and Canaani, E. Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene, 7: 1853-1857, 1992.
45. Gerwin, B. I., Spillare, E., Forrester, K., Lehman, T. A., Kispert, J., Welsh, J. A., Pfeifer, A. M., Lechner, J. F., Baker, S. J., Vogelstein, B., et al. Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor β-1. Proc. Natl. Acad. Sci. USA, 89: 2759-2763, 1992.
46. Kastan, M. B., Radin, A. I., Kuerbitz, S. J., Onyekwere, O., Wolkow, C. A., Civin, C. I., Stone, K. D., Woo, T., Ravindranath, Y., and Craig, R. W. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res., 51: 4279-4286, 1991.
47. Shaulsky, G., Goldfinger, N., and Rotter, V. Alterations in tumor development in vivo mediated by expression of wild-type or mutant p53 proteins. Cancer Res., 51: 5232-5237, 1991.
48. Shaulsky, G., Goldfinger, N., Peled, A., and Rotter, V. Involvement of wild-type p53 in pre-B-cell differentiation in vitro. Proc. Natl. Acad. Sci. USA, 88: 8982-8986, 1991.
49. Radinsky, R., Fidler, I. J., Price, J. E., Esumi, N., Tsan, R., Petty, C. M., Bucana, C. D., and Bar-Eli, M. Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild-type p53. Oncogene, 9: 1877-1883, 1994.
50. Woodworth, C. D., Wang, H., Simpson, S., Alvarez-Salas, L. M., and Notario, V. Overexpression of wild-type p53 alters growth and differentiation of normal human keratinocytes but not human papillomavirus-expressing cell lines. Cell Growth Differ., 4: 367-376, 1993.
51. Donehower, L A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356: 215-221, 1992.
52. Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., and Weinberg, R. A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4: 1-7, 1994.
53. Kaufman, M. H., Kaufman, D. B., Brune, R. M., Stark, M., Armstrong, J. F., and Clarke, A. R. Analysis of fused maxillary incisor dentition in p53-deficient exencephalic mice. J. Anat., 191: 57-64, 1997.
54. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
55. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
56. Finlay, C. A., Hinds, P. W., and Levine, A. J. Thep53 proto-oncogene can act as a suppressor of transformation. Cell, 57: 1083-1093, 1989.
57. Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., and Oren, M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA, 86: 8763-8767, 1989.
58. Michalovitz, D., Halevy, O., and Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62: 671-680, 1990.
59. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumour suppressor gene. Nature (Lond.), 351: 453-456, 1991.
60. Holtzer, H., Schultheiss, T., Dilullo, C., Choi, J., Costa, M., Lu, M., and Holtzer, S. Autonomous expression of the differentiation programs of cells in the cardiac and skeletal myogenic lineages. Ann. N.Y. Acad, Sci., 599: 158-169, 1990.
61. Rumyantsev, P. P., and Borisov, A. DNA synthesis in myocytes from different myocardial compartments of young rats in norm, after experimental infarction and in vitro. Biomed. Biochim. Acta, 46: S610-S615, 1987.
62. Clubb, F. J., Jr., and Bishop, S. P. Formation of binucleated myocardial cells in the neonatal rat. An index for growth hypertrophy. Lab. Invest., 50: 571-577, 1984.
63. Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., and Jacks, T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev., 9: 935-944, 1995.
64. Zhang, W., Behringer, R. R., and Olson, E. N. Inactivation of the myogenic bHLH gene MRF4 results in up-regulation of myogenin and rib anomalies. Genes Dev., 9: 1388-1399, 1995.
65. Lassar, A., and Munsterberg, A. Wiring diagrams: regulatory circuits and the control of skeletal myogenesis. Curr. Opin. Cell Biol., 6: 432-442, 1994.
66. Levine, A. J., Wu, M. C., Chang, A., Silver, A., Attiyeh, E. F., Lin, J., and Epstein, C. B. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Ann. N.Y. Acad. Sci., 768: 111-128, 1995.
67. Frazier, M. W., He, X., Wang, J., Gu, Z., Cleveland, J. L., and Zambetti, G. P. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol. Cell. Biol., 18: 3735-3743, 1998.
68. Gualberto, A., Hixon, M. L., Finco, T. S., Perkins, N. D., Nabel, G. J., and Baldwin, A. S., Jr. A proliferates p53-responsive element mediates tumor necrosis factor α induction of the human immunodeficiency virus type 1 long terminal repeat. Mol. Cell. Biol., 15: 3450-3459, 1995.
69. Gualberto, A., LePage, D., Pons, G., Mader, S. L., Park, K., Atchison, M. L., and Walsh, K. Functional antagonism between YY1 and the serum response factor. Mol. Cell. Biol., 12: 4209-4214, 1992.
70. Newman, J. R., Morency, C. A., and Russian, K. O. A novel rapid assay for chloramphenicol acetyltransferase gene expression. Biotechniques, 5: 444-448, 1987.
71. Vincent, C. K., Gualberto, A., Patel, C. V., and Walsh, K. Different regulatory sequences control creatine kinase-M gene expression in directly injected skeletal and cardiac muscle. Mol. Cell. Biol., 13: 1264-1272, 1993.
72. Hemsley, A., Amheim, N., Toney, M. D., Cortopassi, G., and Galas, D. J. A simple method for site-directed mutagenesis using the polymerase chain reaction. Nucleic Acids Res., 17: 6545-6551, 1989.
73. Knowlton, K. U., Baracchini, E., Ross, R. S., Harris, A. N., Henderson, S. A., Evans, S. M., Glembotski, C. C., and Chien, K. R. Co-regulation of the atrial natriuretic factor and cardiac myosin light chain-2 genes during α-adrenergic stimulation of neonatal rat ventricular cells. Identification of cis sequences within an embryonic and a constitutive contractile protein gene which mediate inducible expression. J. Biol. Chem., 266: 7759-7768, 1991.
74. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
75. Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., and Vogelstein, B. Identification of p53 as a sequence-specific DNA-binding protein. Science (Washington DC), 252: 1708-1711, 1991.
76. Morgenstern, J. P., and Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res., 18: 3587-3596, 1990.
77. Christy, R. J., Yang, V. W., Ntambi, J. M., Geiman, D. E., Landschulz, W. H., Friedman, A. D., Nakabeppu, Y., Kelly, T. J., and Lane, M. D. Differentiation-induced gene expression in 3T3-L1 preadipocytes: CCAAT/enhancer binding protein interacts with and activates the promot-ers of two adipocyte-specific genes. Genes Dev., 3: 1323-1335, 1989.
78. Nabel, G., and Baltimore, D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (Lond.), 326: 711-713, 1987.
79. Lyons, G. E., Micales, B. K., Schwarz, J., Martin, J. F., and Olson, E. N. Expression of mef2 genes in the mouse central nervous system suggests a role in neuronal maturation. J. Neurosci., 15: 5727-5738, 1995.